<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179672</url>
  </required_header>
  <id_info>
    <org_study_id>13649</org_study_id>
    <secondary_id>F1J-MC-HMGV</secondary_id>
    <nct_id>NCT01179672</nct_id>
  </id_info>
  <brief_title>A Study in Participants With Diabetic Peripheral Neuropathic Pain in China</brief_title>
  <official_title>Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once
      daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as
      measured by the weekly mean of the daily pain scores recorded in the participant's diary in
      participants with diabetic peripheral neuropathic pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>24-hour average pain severity scores were recorded daily by the participant on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). The weekly mean was calculated. A negative change indicated an improvement in participant's condition. Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at 12-Week Endpoint in Weekly Mean of Night Pain and Worst Pain</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>24-hour average night pain and worst pain severity scores were recorded daily on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as the baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at 12-Week Endpoint in the BPI-Severity Scale</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>BPI-Severity Scale was a self-reported scale that measured the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at 12-Week Endpoint in the CGI-S Scale</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>CGI-S was administered by the investigator in the presence of the participant and measured the severity of illness at the time of assessment compared with start of treatment; CGI-S scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) Scale at 12-Week Endpoint</measure>
    <time_frame>12 weeks</time_frame>
    <description>PGI-I was self-reported and measured a participant's perception of improvement at the time of assessment compared with the start of treatment. Scores ranged from 1 (very much better) to 7 (very much worse). LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at 12-Week Endpoint in the Sensory Subscale of the SF-MPQ</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>SF-MPQ was a self-reported instrument that consisted of 11 sensory descriptors describing pain. The descriptors were rated on an intensity scale from 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Three (3) pain scores were derived from the sum of the intensity rank values of the words chosen for sensory descriptors. The SF-MPQ sensory subscale was the sum of the 11 scores (ranged from 0 to 33, with 33 being the worst pain). A negative change indicates an improvement. LS mean was calculated using analysis of covariance (ANCOVA) adjusted for treatment, pooled investigator and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-Week Endpoint in Weekly Mean of Average Daily Pain</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>24-hour self-assessment of average daily pain was recorded in the participants diary based on an 11 point Likert scale with scores ranging from 0 (no pain) to 10 (worst possible pain). Percentage of participants was calculated as: (number of participants with 30% [or 50% or 75%] reduction in average daily pain) divided by (number of participants) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-week Endpoint in BPI-Severity Average Pain Score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>BPI-Severity scale was a self-reported scale that measured the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. Percentage of participants was calculated as: (number of participants with 30% [or 50% or 75%] reduction in BPI-Severity average pain) divided by (number of participants) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at 12-week Endpoint in the BPI Interference Score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>BPI-Interference Score was a self-reported scale that measured the interference of pain based on the average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average interference scores ranged from 0 (does not interfere) to 10 (completely interferes). A negative change indicates an improvement in the participant's condition. LS means was calculated using MMRM and adjusted treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>SDS was self-reported and used to assess the effect of the participant's symptoms on their work (Item 1), social life (Item 2), and family life (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. SDS total score was the sum of the 3 items and ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Scores â‰¥5 were associated with significant functional impairment. A negative change indicated an improvement in the participant's condition. LS mean was adjusted using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Diabetic Neuropathy, Painful</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
    <other_name>LY248686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with pain due to bilateral peripheral neuropathy

               -  Participants must have pain caused by Type 1 or Type 2 diabetes mellitus

               -  Pain must begin in the feet with relatively symmetrical onset

               -  Daily pain should be present for at least 6 months

               -  Diagnosis must be confirmed by a score of at least 3 on the Michigan Neuropathy
                  Screening Inventory (MNSI)

          -  Females must test negative for a serum pregnancy test at Screening. Females of
             child-bearing potential (who are not surgically sterilized and between menarche and 1
             year postmenopause) must agree to use a medically acceptable and reliable means of
             birth control, during the study and for 1 month following the last study dose.

          -  Stable glycemic control as assessed by a physician investigator and a glycosylated
             hemoglobin (HbA1c) &lt;12% before randomization

          -  Score of greater than or equal to 4 on the Brief Pain Inventory (BPI) 24-hour average
             pain item at Screening.

          -  Full completion of the daily diaries for at least 80% of the days between the second
             and third time you come to the hospital (Screening).

        Exclusion Criteria:

          -  Currently enrolled in, or discontinued within the last 30 days from, a clinical trial
             involving an investigational drug or device or off-label use of a drug or device, or
             concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study

          -  Current (less than or equal to 1 year) Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition (DSM-IV) Axis I diagnosis of major depressive disorder,
             dysthymia, anxiety disorders (excluding phobias), alcohol or eating disorders as
             determined by the Mini-International Neuropsychiatric Interview (MINI) or a previous
             diagnosis

          -  DSM-IV diagnosis of mania, bipolar disorder, or psychosis determined either by
             participant history or by diagnosis using specific MNSI modules

          -  Serious or unstable cardiovascular, hepatic, renal, respiratory, or hematologic
             illness, symptomatic peripheral vascular disease, or other medical condition or
             psychological conditions that in the opinion of investigator would compromise
             participation or be likely to lead to hospitalization during the course of the study.

          -  At Screening alanine transaminase (ALT) greater than 2 times upper limit of normal
             (ULN), based on central laboratory reference ranges times ULN, based on central
             laboratory reference ranges

          -  Prior renal transplant, current renal dialysis, or serum creatinine laboratory value
             &gt;1.5 times ULN, based on central laboratory reference ranges at Screening.

          -  Historical exposure to drugs known to cause neuropathy, or a history of a medical
             condition, including pernicious anemia and hypothyroidism, that could have been
             responsible for neuropathy

          -  Pain that cannot be clearly differentiated from or conditions that interfere with the
             assessment of the diabetic neuropathy pain. Examples of painful conditions that could
             be confused with diabetic neuropathy pain include peripheral vascular disease,
             neurological disorders unrelated to diabetic neuropathy, skin condition in the area of
             the neuropathy that could alter sensation, other painful conditions

          -  Participants who have previously completed or withdrawn from this study or have been
             previously treated with duloxetine, including participants who participated in study
             F1J-MC-HMEQ (NCT00408993), even those in the placebo arm

          -  Participants taking excluded medications that cannot be stopped at Screening

          -  Treatment with a monoamine oxidase inhibitor (MAOI) or fluoxetine within 30 days of
             the third Screening

          -  Participants with a positive Hepatitis B surface antigen and/or Hepatitis C antibody
             are to be excluded if they have any of the following:

               -  Hepatic dysfunction as determined by the investigator or

               -  Clinical manifestations of liver disease within the previous year such as
                  unexplained pruritus, unexplained dark urine, jaundice, unexplained right upper
                  quadrant tenderness, unexplained &quot;flu-like&quot; symptoms or

               -  Aspartate transaminase (AST), ALT, or bilirubin above the normal reference range.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bengbu</city>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chengdu</city>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jinan</city>
        <zip>250001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjin</city>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Qingdao</city>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shantou</city>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shi Jia Zhuang</city>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Xi'An</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yueyang</city>
        <zip>414000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <results_first_submitted>June 12, 2014</results_first_submitted>
  <results_first_submitted_qc>June 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2014</results_first_posted>
  <last_update_submitted>October 3, 2014</last_update_submitted>
  <last_update_submitted_qc>October 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Peripheral Neuropathic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants tapered off study drug after either completing the 12 weeks of treatment or discontinued treatment early.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine</title>
          <description>30 milligrams (mg) duloxetine capsule administered orally, once daily (QD) during Week 1 then 60 mg duloxetine capsule orally, QD for the remaining 11 weeks of treatment. After a total 12 weeks of treatment or early discontinuation participants tapered off study drug (30 mg duloxetine capsule QD) for 1 week during taper.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Taper</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine</title>
          <description>30 mg duloxetine capsule administered orally, QD during Week 1 then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="203"/>
            <count group_id="B2" value="202"/>
            <count group_id="B3" value="405"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.56" spread="9.65"/>
                    <measurement group_id="B2" value="61.17" spread="9.42"/>
                    <measurement group_id="B3" value="61.37" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Disease Characteristics-Types of Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type I Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type II Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Disease Characteristics</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Duration of Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.53" spread="6.81"/>
                    <measurement group_id="B2" value="11.38" spread="7.47"/>
                    <measurement group_id="B3" value="11.45" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Diabetic Neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.47" spread="3.91"/>
                    <measurement group_id="B2" value="3.07" spread="3.13"/>
                    <measurement group_id="B3" value="3.27" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Diabetic Neuropathy Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.06" spread="3.70"/>
                    <measurement group_id="B2" value="2.59" spread="2.69"/>
                    <measurement group_id="B3" value="2.83" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weekly Mean of 24-Hour Average Pain</title>
          <description>Participants measured their pain on an 11-point Likert scale that was completed daily. The scale ranged from 0 (no pain) to 10 (worst possible pain). The participant-recorded average pain due to diabetic neuropathy over the previous 24 hours.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.72" spread="1.72"/>
                    <measurement group_id="B2" value="5.62" spread="1.66"/>
                    <measurement group_id="B3" value="5.67" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Pain Inventory (BPI)-Severity Average Pain in the Last Week</title>
          <description>BPI-Severity Modified Short Form Severity was a self-reported scale that measured the severity of pain. Severity scores ranged from 0 (no pain) to 10 (pain as bad as you could imagine). There were 4 questions assessing the severity for worst pain, least pain, average pain, and the pain right now.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.97" spread="1.70"/>
                    <measurement group_id="B2" value="5.86" spread="1.64"/>
                    <measurement group_id="B3" value="5.91" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression of Severity (CGI-S)</title>
          <description>Number of participants analyzed was: Duloxetine treatment =126 and Placebo=136. Data from 9 sites were not included in baseline analysis due to wrong questionnaire used. CSI-S was administered by the investigator in the presence of the participant and measured severity of illness at baseline with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.76" spread="1.22"/>
                    <measurement group_id="B2" value="4.66" spread="1.07"/>
                    <measurement group_id="B3" value="4.71" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form-McGill Pain Questionnaire (SF-MPQ), Sensory Portion Total Score</title>
          <description>SF-MPQ sensory portion was a self-reported instrument consisting of 11 sensory descriptors describing pain, each rated on an intensity scale from 0 (none) to 3 (severe). Total scores ranged from 0 to 33.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.24" spread="6.39"/>
                    <measurement group_id="B2" value="11.81" spread="5.52"/>
                    <measurement group_id="B3" value="12.02" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BPI-Interference Average Score</title>
          <description>BPI-Interference Score was self-reported scale that measured interference of pain based on the average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average interference scores ranged from 0 (does not interfere) to 10 (completely interferes).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.38" spread="2.29"/>
                    <measurement group_id="B2" value="4.08" spread="2.30"/>
                    <measurement group_id="B3" value="4.23" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sheehan Disability Scale (SDS) Total Score</title>
          <description>SDS was self-reported and used to assess the effect of the participant's symptoms on their work (Item 1), social life (Item 2), and family life (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. SDS Total Score was the sum of the 3 items and ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Scores â‰¥5 were associated with significant functional impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.16" spread="7.59"/>
                    <measurement group_id="B2" value="10.54" spread="7.31"/>
                    <measurement group_id="B3" value="10.85" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score</title>
        <description>24-hour average pain severity scores were recorded daily by the participant on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). The weekly mean was calculated. A negative change indicated an improvement in participant's condition. Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Intent-to-treat (ITT) principle was applied: All participants with a baseline and 12-week 24-hour average pain score based on the randomized group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score</title>
          <description>24-hour average pain severity scores were recorded daily by the participant on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). The weekly mean was calculated. A negative change indicated an improvement in participant's condition. Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>Intent-to-treat (ITT) principle was applied: All participants with a baseline and 12-week 24-hour average pain score based on the randomized group were analyzed.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.40" spread="0.14"/>
                    <measurement group_id="O2" value="-1.97" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at 12-Week Endpoint in Weekly Mean of Night Pain and Worst Pain</title>
        <description>24-hour average night pain and worst pain severity scores were recorded daily on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as the baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>ITT principle was applied: All participants with a baseline and 12-week 24-hour night pain score and worst pain score based on the randomized group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at 12-Week Endpoint in Weekly Mean of Night Pain and Worst Pain</title>
          <description>24-hour average night pain and worst pain severity scores were recorded daily on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as the baseline score and baseline score-by-visit interaction.</description>
          <population>ITT principle was applied: All participants with a baseline and 12-week 24-hour night pain score and worst pain score based on the randomized group were analyzed.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Night Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="0.15"/>
                    <measurement group_id="O2" value="-2.11" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="0.16"/>
                    <measurement group_id="O2" value="-2.25" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value is for mean change from baseline to 12-week endpoint in night pain.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-value is for mean change from baseline to 12 week endpoint in worst pain.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at 12-Week Endpoint in the BPI-Severity Scale</title>
        <description>BPI-Severity Scale was a self-reported scale that measured the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>ITT principle was applied: All participants with a baseline and 12-week, 24-hour BPI-Severity score based on the randomized group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at 12-Week Endpoint in the BPI-Severity Scale</title>
          <description>BPI-Severity Scale was a self-reported scale that measured the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>ITT principle was applied: All participants with a baseline and 12-week, 24-hour BPI-Severity score based on the randomized group were analyzed.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="0.15"/>
                    <measurement group_id="O2" value="-2.00" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at 12-Week Endpoint in the CGI-S Scale</title>
        <description>CGI-S was administered by the investigator in the presence of the participant and measured the severity of illness at the time of assessment compared with start of treatment; CGI-S scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>ITT principle was applied: All participants with a baseline and 12-week CGI-S score based on the randomized group were analyzed. Data from 9 sites was not included in analysis due to wrong questionnaire used.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at 12-Week Endpoint in the CGI-S Scale</title>
          <description>CGI-S was administered by the investigator in the presence of the participant and measured the severity of illness at the time of assessment compared with start of treatment; CGI-S scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>ITT principle was applied: All participants with a baseline and 12-week CGI-S score based on the randomized group were analyzed. Data from 9 sites was not included in analysis due to wrong questionnaire used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="0.10"/>
                    <measurement group_id="O2" value="-1.17" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) Scale at 12-Week Endpoint</title>
        <description>PGI-I was self-reported and measured a participant's perception of improvement at the time of assessment compared with the start of treatment. Scores ranged from 1 (very much better) to 7 (very much worse). LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>12 weeks</time_frame>
        <population>All participants with a baseline and 12-week PGI-I score.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) Scale at 12-Week Endpoint</title>
          <description>PGI-I was self-reported and measured a participant's perception of improvement at the time of assessment compared with the start of treatment. Scores ranged from 1 (very much better) to 7 (very much worse). LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>All participants with a baseline and 12-week PGI-I score.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.07"/>
                    <measurement group_id="O2" value="2.65" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at 12-Week Endpoint in the Sensory Subscale of the SF-MPQ</title>
        <description>SF-MPQ was a self-reported instrument that consisted of 11 sensory descriptors describing pain. The descriptors were rated on an intensity scale from 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Three (3) pain scores were derived from the sum of the intensity rank values of the words chosen for sensory descriptors. The SF-MPQ sensory subscale was the sum of the 11 scores (ranged from 0 to 33, with 33 being the worst pain). A negative change indicates an improvement. LS mean was calculated using analysis of covariance (ANCOVA) adjusted for treatment, pooled investigator and baseline.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>ITT principle was applied: All participants with a baseline and 12 weeks SF-MPQ score based on the randomized group were analyzed; last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at 12-Week Endpoint in the Sensory Subscale of the SF-MPQ</title>
          <description>SF-MPQ was a self-reported instrument that consisted of 11 sensory descriptors describing pain. The descriptors were rated on an intensity scale from 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Three (3) pain scores were derived from the sum of the intensity rank values of the words chosen for sensory descriptors. The SF-MPQ sensory subscale was the sum of the 11 scores (ranged from 0 to 33, with 33 being the worst pain). A negative change indicates an improvement. LS mean was calculated using analysis of covariance (ANCOVA) adjusted for treatment, pooled investigator and baseline.</description>
          <population>ITT principle was applied: All participants with a baseline and 12 weeks SF-MPQ score based on the randomized group were analyzed; last observation carried forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.45" spread="0.36"/>
                    <measurement group_id="O2" value="-5.33" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment, pooled investigator and baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.07</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-Week Endpoint in Weekly Mean of Average Daily Pain</title>
        <description>24-hour self-assessment of average daily pain was recorded in the participants diary based on an 11 point Likert scale with scores ranging from 0 (no pain) to 10 (worst possible pain). Percentage of participants was calculated as: (number of participants with 30% [or 50% or 75%] reduction in average daily pain) divided by (number of participants) multiplied by 100.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All participants with a baseline and postbaseline 24-hour average pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-Week Endpoint in Weekly Mean of Average Daily Pain</title>
          <description>24-hour self-assessment of average daily pain was recorded in the participants diary based on an 11 point Likert scale with scores ranging from 0 (no pain) to 10 (worst possible pain). Percentage of participants was calculated as: (number of participants with 30% [or 50% or 75%] reduction in average daily pain) divided by (number of participants) multiplied by 100.</description>
          <population>All participants with a baseline and postbaseline 24-hour average pain score.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>â‰¥30% Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥50% Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                    <measurement group_id="O2" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥75% Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>P-value is for â‰¥30% reduction in 24-hour average pain.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test was stratified by pooled investigator.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-value is for â‰¥50% reduction in 24-hour average pain.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test was stratified by pooled investigator.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.193</p_value>
            <p_value_desc>P-value is for â‰¥75% reduction in 24-hour average pain.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test was stratified by pooled investigator.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-week Endpoint in BPI-Severity Average Pain Score</title>
        <description>BPI-Severity scale was a self-reported scale that measured the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. Percentage of participants was calculated as: (number of participants with 30% [or 50% or 75%] reduction in BPI-Severity average pain) divided by (number of participants) multiplied by 100.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All participants with a baseline and postbaseline BPI-Severity average pain scores.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-week Endpoint in BPI-Severity Average Pain Score</title>
          <description>BPI-Severity scale was a self-reported scale that measured the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. Percentage of participants was calculated as: (number of participants with 30% [or 50% or 75%] reduction in BPI-Severity average pain) divided by (number of participants) multiplied by 100.</description>
          <population>All participants with a baseline and postbaseline BPI-Severity average pain scores.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>â‰¥30% Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0"/>
                    <measurement group_id="O2" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥50% Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥75% Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is for â‰¥30% reduction in 24-hour BPI-Severity average pain.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test was stratified by pooled investigator.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for â‰¥50% reduction in 24-hour BPI-Severity average pain.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test was stratified by pooled investigator.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <p_value_desc>P-value is for â‰¥75% reduction in 24-hour BPI-Severity average pain.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran Mantel Haenszel test was stratified by pooled investigator.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at 12-week Endpoint in the BPI Interference Score</title>
        <description>BPI-Interference Score was a self-reported scale that measured the interference of pain based on the average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average interference scores ranged from 0 (does not interfere) to 10 (completely interferes). A negative change indicates an improvement in the participant's condition. LS means was calculated using MMRM and adjusted treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All participants with non-missing BPI-Interference score at baseline and 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at 12-week Endpoint in the BPI Interference Score</title>
          <description>BPI-Interference Score was a self-reported scale that measured the interference of pain based on the average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average interference scores ranged from 0 (does not interfere) to 10 (completely interferes). A negative change indicates an improvement in the participant's condition. LS means was calculated using MMRM and adjusted treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.</description>
          <population>All participants with non-missing BPI-Interference score at baseline and 12 weeks.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="0.13"/>
                    <measurement group_id="O2" value="-1.82" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score</title>
        <description>SDS was self-reported and used to assess the effect of the participant's symptoms on their work (Item 1), social life (Item 2), and family life (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. SDS total score was the sum of the 3 items and ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Scores â‰¥5 were associated with significant functional impairment. A negative change indicated an improvement in the participant's condition. LS mean was adjusted using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All participants with non-missing SDS Total Score at baseline and 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score</title>
          <description>SDS was self-reported and used to assess the effect of the participant's symptoms on their work (Item 1), social life (Item 2), and family life (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. SDS total score was the sum of the 3 items and ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Scores â‰¥5 were associated with significant functional impairment. A negative change indicated an improvement in the participant's condition. LS mean was adjusted using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.</description>
          <population>All participants with non-missing SDS Total Score at baseline and 12 weeks.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.36" spread="0.40"/>
                    <measurement group_id="O2" value="-5.09" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine Treatment</title>
          <description>30 mg duloxetine capsule administered orally, QD during Week 1 of the treatment; 60 mg capsule administered orally, QD for remaining 11 weeks of the treatment;</description>
        </group>
        <group group_id="E2">
          <title>Placebo Treatment</title>
          <description>Placebo administered orally, QD for 12 weeks of the treatment.</description>
        </group>
        <group group_id="E3">
          <title>Duloxetine Taper</title>
          <description>After 12 weeks of treatment or early discontinuation, 30 mg duloxetine capsule administered orally, QD for 1 week during taper.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Taper</title>
          <description>After 12 weeks of treatment or early discontinuation, placebo administered orally, QD for 1 week during taper.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Sluggishness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Fatty liver alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cauda equina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood cholesterol decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Clonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Diabetic autonomic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dreamy state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Formication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Fear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Food aversion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Illusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Mutism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

